Abstract
Nanoparticle drug formulations (NDFs) allow for local and durable release of cancer therapeutics, and hold tremendous promise for advancing the efficacy of cancer treatment strategies. NDFs can be administered to patients via a variety of routes, the most common of which is intravenous injection. Unfortunately, the systemic nature of this approach can result in off-target toxicity. Furthermore, many cancers cannot be accessed by intravenous administration. Consequently, recent efforts have applied anatomical targeting strategies to deliver NDFs directly to cancerous lesions. These non-conventional routes of administration can increase the bioavailability of therapeutics while reducing off-target side effects. Importantly, the considerations that underlie NDF design for each anatomical targeting strategy are unique due to obstacles specific to different organs and delivery devices. Clinical trials reporting upon non-conventional administration of NDFs and preclinical studies investigating novel administration techniques are very encouraging. This chapter will discuss the current state and practice of cancer treatment approaches utilizing non-conventional NDF administration.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schroeder, A., Heller, D.A., Winslow, M.M., Dahlman, J.E., Pratt, G.W., Langer, R., Jacks, T., Anderson, D.G.: Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 12(1), 39–50 (2011). https://doi.org/10.1038/nrc3180
Shi, J., Kantoff, P.W., Wooster, R., Farokhzad, O.C.: Cancer nanomedicine: progress, challenges and opportunities. Nat. Publ. Group. 17, 1–18 (2016). https://doi.org/10.1038/nrc.2016.108
Cheng, C.J., Tietjen, G.T., Saucier-Sawyer, J.K., Saltzman, W.M.: A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 14, 239–247 (2015). https://doi.org/10.1038/nrd4503
Lee, W.-H., Loo, C.-Y., Traini, D., Young, P.M.: Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges. Asian J. Pharm. Sci. 10, 481–489 (2015). https://doi.org/10.1016/j.ajps.2015.08.009
Johnson, D.H., Schiller, J.H., Bunn, P.A.: Recent clinical advances in lung cancer management. J. Clin. Oncol. 32, 973–982 (2014). https://doi.org/10.1200/JCO.2013.53.1228
Labiris, N.R., Dolovich, M.B.: Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56, 600–612 (2003). https://doi.org/10.1046/j.1365-2125.2003.01893.x
Ruge, C.A., Kirch, J., Lehr, C.-M.: Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir. Med. 1, 402–413 (2013). https://doi.org/10.1016/S2213-2600(13)70072-9
Zarogoulidis, P., Chatzaki, E., Porpodis, K., Domvri, K., Hohenforst-Schmidt, W., Goldberg, E.P., Karamanos, N., Zarogoulidis, K.: Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomedicine. 7, 1551–1522 (2012). https://doi.org/10.2147/IJN.S29997
Rudokas, M., Najlah, M., Alhnan, M.A., Elhissi, A.: Liposome delivery Systems for Inhalation: a critical review highlighting formulation issues and anticancer applications. Med. Princ. Pract. 25, 60–72 (2016). https://doi.org/10.1159/000445116
Ungaro, F., d'Angelo, I., Coletta, C., di Villa Bianca, R.D., Sorrentino, R., Perfetto, B., Tufano, M.A., Miro, A., La Rotonda, M.I., Quaglia, F.: Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release. 157, 149–159 (2012). https://doi.org/10.1016/j.jconrel.2011.08.010
Muralidharan, P., Malapit, M., Mallory, E., Hayes Jr., D., Mansour, H.M.: Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine. 11, 1189–1199 (2015). https://doi.org/10.1016/j.nano.2015.01.007
Loira-Pastoriza, C., Todoroff, J., Vanbever, R.: Delivery strategies for sustained drug release in the lungs. Adv. Drug Deliv. Rev. 75, 81–91 (2014). https://doi.org/10.1016/j.addr.2014.05.017
Sturm, R.: Spatial visualization of theoretical nanoparticle deposition in the human respiratory tract. Ann. Transl. Med. 3, 326 (2015). https://doi.org/10.3978/j.issn.2305-5839.2015.12.19
Kleinstreuer, C.: Drug-targeting methodologies with applications: a review. World J. Clin. Cases. 2, 742–716 (2014). https://doi.org/10.12998/wjcc.v2.i12.742
van Rijt, S.H., Bein, T., Meiners, S.: Medical nanoparticles for next generation drug delivery to the lungs. Eur. Respir. J. 44, 765–774 (2014). https://doi.org/10.1183/09031936.00212813
Lai, S.K., Wang, Y.-Y., Hanes, J.: Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158–171 (2009). https://doi.org/10.1016/j.addr.2008.11.002
Liu, M., Zhang, J., Shan, W., Huang, Y.: Developments of mucus penetrating nanoparticles. Asian J. Pharm. Sci. 10, 275–282 (2015). https://doi.org/10.1016/j.ajps.2014.12.007
Suk, J.S., Lai, S.K., Boylan, N.J., Dawson, M.R., Boyle, M.P., Hanes, J.: Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine. 6, 365–375 (2011). https://doi.org/10.2217/nnm.10.123
Patel, B., Gupta, N., Ahsan, F.: Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. Eur. J. Pharm. Biopharm. 89, 163–174 (2015). https://doi.org/10.1016/j.ejpb.2014.12.001
Champion, J.A., Mitragotri, S.: Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U. S. A. 103, 4930–4934 (2006). https://doi.org/10.1073/pnas.0600997103
Skubitz, K.M., Anderson, P.M.: Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anti-Cancer Drugs. 11, 555–563 (2000)
Verschraegen, C.F., Gilbert, B.E., Loyer, E., Huaringa, A., Walsh, G., Newman, R.A., Knight, V.: Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. 10, 2319–2326 (2004)
Wittgen, B.P.H., Kunst, P.W.A., van der Born, K., van Wijk, A.W., Perkins, W., Pilkiewicz, F.G., Perez-Soler, R., Nicholson, S., Peters, G.J., Postmus, P.E.: Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res. 13, 2414–2421 (2007). https://doi.org/10.1158/1078-0432.CCR-06-1480
Chou, A.J., Gupta, R., Bell, M.D., Riewe, K.O., Meyers, P.A., Gorlick, R.: Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr. Blood Cancer. 60, 580–586 (2012). https://doi.org/10.1002/pbc.24438
Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O.B., Minko, T.: Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release. 171, 349–357 (2013). https://doi.org/10.1016/j.jconrel.2013.04.018
Kim, I., Byeon, H.J., Kim, T.H., Lee, E.S., Oh, K.T., Shin, B.S., Lee, K.C., Youn, Y.S.: Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials. 34, 6444–6453 (2013). https://doi.org/10.1016/j.biomaterials.2013.05.018
Revia, R.A., Zhang, M.: Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances. Biochem. Pharmacol. 19, 157–168 (2016). https://doi.org/10.1016/j.mattod.2015.08.022
Kaliki, S., Shields, C.L.: Uveal melanoma: relatively rare but deadly. Cancer. 31, 1–17 (2016). https://doi.org/10.1038/eye.2016.275
Jovanovic, P., Mihajlovic, M., Djordjevic-Jocic, J., Vlajkovic, S., Cekic, S., Stefanovic, V.: Ocular melanoma: an overview of the current status. Int. J. Clin. Exp. Pathol. 6, 1230–1244 (2013)
Abramson, D.H., Daniels, A.B., Marr, B.P., Francis, J.H., Brodie, S.E., Dunkel, I.J., Gobin, Y.P.: Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma. PLoS One. 11, e0146582 (2016). https://doi.org/10.1371/journal.pone.0146582
You, S., Luo, J., Grossniklaus, H.E., Gou, M.L.: Nanomedicine in the application of uveal melanoma. Int. J. Ophthalmol. 9, 1215–1225 (2016). https://doi.org/10.18240/ijo.2016.08.20
Reimondez-Troitiño, S., Csaba, N., Alonso, M.J., la Fuente de, M.: Nanotherapies for the treatment of ocular diseases. Eur. J. Pharm. Biopharm. 95, 279–293 (2015). https://doi.org/10.1016/j.ejpb.2015.02.019
Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., Hu, Z.: Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm. Sin. B. 7, 281–291 (2017). https://doi.org/10.1016/j.apsb.2016.09.001
Kompella, U.B., Amrite, A.C., Pacha Ravi, R., Durazo, S.A.: Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog. Retin. Eye Res. 36, 172–198 (2013). https://doi.org/10.1016/j.preteyeres.2013.04.001
Patel, A.: Ocular drug delivery systems: an overview. World J. Pharmacol. 2, 47–35 (2013). https://doi.org/10.5497/wjp.v2.i2.47
Martens, T.F., Remaut, K., Deschout, H.: Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J Control Release. 202, 83–92 (2015). https://doi.org/10.1016/j.jconrel.2015.01.030
Prow, T.W.: Toxicity of nanomaterials to the eye. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 317–333 (2010). https://doi.org/10.1002/wnan.65
Shome, D., Kalita, D., Jain, V., Sarin, R.: Carboplatin loaded polymethylmethacrylate nano-particles in an adjunctive role in retinoblastoma: an animal trial. J. Control Release. 62, 585 (2014). https://doi.org/10.4103/0301-4738.129792
Kalita, D., Shome, D., Jain, V.G., Chadha, K., Bellare, J.R.: In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. Am J. Ophthalmol. 157, 1109–1115 (2014). https://doi.org/10.1016/j.ajo.2014.01.027
Kang, S.J.: Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch. Ophthalmol. 127, 1043–1049 (2009). https://doi.org/10.1001/archophthalmol.2009.185
Furst, T., Evrard, B., Delvenne, P., Hubert, P., Piel, G.: Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions. Int. J. Pharm. 483, 268–277 (2015). https://doi.org/10.1016/j.ijpharm.2015.02.041
Christie, J.G., Kompella, U.B.: Ophthalmic light sensitive nanocarrier systems. Drug Discov. Today. 13, 124–134 (2008). https://doi.org/10.1016/j.drudis.2007.12.005
Gallud, A.: Functionalized nanoparticles for drug delivery, one- and two-photon photodynamic therapy as a promising treatment of retinoblastoma. J. Clin. Exp. Ophthalmol. 04, 1–4 (2013). https://doi.org/10.4172/2155-9570.1000288
Wang, Z.-J., Chauvin, B., Maillard, P., Hammerer, F., Carez, D., Croisy, A., Sandré, C., Chollet-Martin, S., Prognon, P., Paul, J.-L., Blais, J., Kasselouri, A.: Glycodendrimeric phenylporphyrins as new candidates for retinoblastoma PDT: blood carriers and photodynamic activity in cells. J. Photochem. Photobiol. B Biol. 115, 16–24 (2012). https://doi.org/10.1016/j.jphotobiol.2012.06.005
Ensign, L.M., Cone, R., Hanes, J.: Nanoparticle-based drug delivery to the vagina: a review. J. Control. Release. 190, 500–514 (2014). https://doi.org/10.1016/j.jconrel.2014.04.033
Blum, J.S., Weller, C.E., Booth, C.J., Babar, I.A., Liang, X., Slack, F.J., Saltzman, W.M.: Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles. Drug Deliv.Transl. Res. 1, 383–394 (2011). https://doi.org/10.1007/s13346-011-0038-y
Yang, M., Yu, T., Wang, Y.-Y., Lai, S.K., Zeng, Q., Miao, B., Tang, B.C., Simons, B.W., Ensign, L.M., Liu, G., Chan, K.W.Y., Juang, C.-Y., Mert, O., Wood, J., Fu, J., McMahon, M.T., Wu, T.C., Hung, C.-F., Hanes, J.: Vaginal delivery of paclitaxel via nanoparticles with non-Mucoadhesive surfaces suppresses cervical tumor growth. Adv. Healthc. Mater. 3, 1044–1052 (2013). https://doi.org/10.1002/adhm.201300519
Büyükköroğlu, G., Şenel, B., Başaran, E., Yenilmez, E., Yazan, Y.: Preparation and in vitro evaluation of vaginal formulations including siRNA and paclitaxel-loaded SLNs for cervical cancer. Eur. J. Pharm. Biopharm. 109, 174–183 (2016). https://doi.org/10.1016/j.ejpb.2016.10.017
De Rosa, M., Pace, U., Rega, D., Costabile, V., Duraturo, F., Izzo, P., Delrio, P.: Genetics, diagnosis and management of colorectal cancer (review). Oncol. Rep. 34, 1–10 (2015). https://doi.org/10.3892/or.2015.4108
Patel, M.M.: Getting into the colon: approaches to target colorectal cancer. Expert Opin. Drug Deliv. 11, 1343–1350 (2014). https://doi.org/10.1517/17425247.2014.927440
Hua, S., Marks, E., Schneider, J.J., Keely, S.: Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 11, 1117–1132 (2015). https://doi.org/10.1016/j.nano.2015.02.018
Kumar, G.V., Kumar, A., Asok Kumar, N., Nair, S.A.: Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon. Int. J. Nanomedicine. 7, 5769–5711 (2012). https://doi.org/10.2147/IJN.S31201
Tummala, S., Kumar, M.N.S., Prakash, A.: Formulation and characterization of 5-fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm. J. 23, 308–314 (2015). https://doi.org/10.1016/j.jsps.2014.11.010
Sinha, V., Singh, A., Kumar, R.V., Singh, S., Kumria, R., Bhinge, J.: Oral colon-specific drug delivery of protein and peptide drugs. Crit. Rev. Ther. Drug Carrier Syst. 24, 63–92 (2007)
Ding, W., Wang, F., Zhang, J., Guo, Y., Ju, S.: A novel local anti-colorectal cancer drug delivery system: negative lipidoid nanoparticles with a passive target via a size-dependent pattern. Nanotechnology. 24, 105102 (2013). https://doi.org/10.1088/0957-4484/24/10/105102
Ilbasmis-Tamer, S., Unsal, H., Tugcu-Demiroz, F., Kalaycioglu, G.D., Degim, I.T., Aydogan, N.: Stimuli-responsive lipid nanotubes in gel formulations for the delivery of doxorubicin. Colloids Surf. B Biointerfaces. 143, 406–414 (2016). https://doi.org/10.1016/j.colsurfb.2016.03.070
Feng, H., Zhu, Y., Li, D.: Formulation and evaluation of irinotecan suppository for rectal administration. Biomol. Ther. 22, 78–81 (2014). https://doi.org/10.4062/biomolther.2013.087
Din, F.U., Choi, J.Y., Kim, D.-W., Mustapha, O., Kim, D.S., Thapa, R.K., Ku, S.K., Youn, Y.S., Oh, K.T., Yong, C.S., Kim, J.O., Choi, H.-G.: Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration. Drug Deliv. 24, 502–510 (2017). https://doi.org/10.1080/10717544.2016.1272651
Tomlinson, B., Lin, T.-Y., Dall'Era, M., Pan, C.-X.: Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine. 10, 1189–1201 (2015). https://doi.org/10.2217/nnm.14.212
Chen, C.-H., Chan, T.-M., Wu, Y.-J., Chen, J.-J.: Review: application of nanoparticles in urothelial Cancer of the urinary bladder. J. Med. Biol. Eng. 35, 419–427 (2015). https://doi.org/10.1007/s40846-015-0060-5
Luo, L., Jin, X., Zhang, P., Cheng, H., Li, Y., Du, T., Zou, B., Gou, M.: Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies. Int. J. Nanomedicine. 11, 4535–4544 (2016). https://doi.org/10.2147/IJN.S103994
Nakamura, T., Fukiage, M., Higuchi, M., Nakaya, A., Yano, I., Miyazaki, J., Nishiyama, H., Akaza, H., Ito, T., Hosokawa, H., Nakayama, T., Harashima, H.: Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J. Control. Release. 176, 44–53 (2014). https://doi.org/10.1016/j.jconrel.2013.12.027
Erdoğar, N., İskit, A.B., Mungan, N.A., Bilensoy, E.: Prolonged retention and in vivoevaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours. J. Microencapsul. 29, 576–582 (2012). https://doi.org/10.3109/02652048.2012.668957
Şenyiğit, Z.A., Karavana, S.Y., Ilem Ozdemir, D., Çalışkan, Ç., Waldner, C., Sen, S., Bernkop-Schnürch, A., Baloglu, E.: Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan/poloxamer gels as carriers. Int. J. Nanomedicine. 10, 6493–6507 (2015). https://doi.org/10.2147/IJN.S93750
Bassi, P.F., Volpe, A., D'Agostino, D., Palermo, G., Renier, D., Franchini, S., Rosato, A., Racioppi, M.: Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study. J. Urol. 185, 445–449 (2011). https://doi.org/10.1016/j.juro.2010.09.073
McKiernan, J.M., Barlow, L.J., Laudano, M.A., Mann, M.J., Petrylak, D.P., Benson, M.C.: A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J. Urol. 186, 448–451 (2011). https://doi.org/10.1016/j.juro.2011.03.129
McKiernan, J.M., Holder, D.D., Ghandour, R.A., Barlow, L.J., Ahn, J.J., Kates, M., Badalato, G.M., Roychoudhury, A., Decastro, G.J., Benson, M.C.: Phase II trial of Intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-GuErin treatment failure. J. Urol. 192, 1633–1638 (2014). https://doi.org/10.1016/j.juro.2014.06.084
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply
About this chapter
Cite this chapter
Roche, K.C., Medik, Y.B., Rodgers, Z., Warner, S., Wang, A.Z. (2019). Cancer Nanotherapeutics Administered by Non-conventional Routes. In: Rai, P., Morris, S.A. (eds) Nanotheranostics for Cancer Applications. Bioanalysis, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-030-01775-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-01775-0_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01773-6
Online ISBN: 978-3-030-01775-0
eBook Packages: EngineeringEngineering (R0)